Anti-Rheumatic Rx
EULAR treats its attendees to a wonderful lunch each day – Schnitzel, gnocchi, goulash at lunch after muffins and coffee in the morning. It's no wonder the meeting has been a lively one, well…
2 weeks 2 days ago
500+ pts AxSPA
No difference in drug discontinuation between IL-17i, TNFi, IL23i over time
Adjusted for CRP, co-medication w/ MTX + classic covariates
IL-17i and IL-23i had experienced a higher number bDMARD failures
#EULAR2024 POS0259 @RheumNow https://t.co/F3B6uXyAca
Multi-modal analysis of rheumatoid arthritis (RA) synovitis pathotypes enables more accurate choices of first line cDMARDs treatment, suggesting a predictive value to synovial biopsy. The…
2 weeks 2 days ago
Leflunomide for #PMR?
✅ #Leflunomide FAR more effective than #MTX in #polymyalgia #rheumatica
V fast withdrawal of #prednisone
#LEF ~4 to 5 months
#MTX 30 mos!
⬇️flares w LEF
😮
#EULAR2024 @RheumNow @eular_org
@SebaUltraTrail https://t.co/2hk0yMH6gY
Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the…
Analysis of French claims data, found over half of women initiating oral bisphosphonates (BP) between 2015 and 2020 discontinued treatment for at least one year, which was associated with a 12%…
Dual seropositivity (rheumatoid factor (RF) and/or anti-citrullinated protein antibodies (ACPA) as well as shared epitope (SE) are known to be associated with poor prognosis and structural damage in…
2 weeks 3 days ago
What happens when RA patients only on csDMARDs want to stop their meds?
in BIO-FLARE, only half flared within 6mo of stopping all csDMARDs suddenly. They’ve got a clinical predictive model. Many milder patients ask, and could benefit!
#EULAR2024 POS0068 John Isaacs @RheumNow https://t.co/B7ZjP5Pj70
Poster Hall